Gustavo Fonseca
Overview
Explore the profile of Gustavo Fonseca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bahlis N, Samaras C, Reece D, Sebag M, Matous J, Berdeja J, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Sep;
24(12):852-862.
PMID: 39237427
Background: Patients with relapsed or refractory multiple myeloma (RRMM) who have exhausted lenalidomide benefits require improved therapies. The 3-cohort phase 2 MM-014 trial (NCT01946477) explored pomalidomide in early lines of...
2.
de Jesus S, Vieira D, Gheller P, Cunha B, Gallucci F, Fonseca G
PeerJ
. 2023 Oct;
11:e16216.
PMID: 37842061
Background: Identifying species, particularly small metazoans, remains a daunting challenge and the phylum Nematoda is no exception. Typically, nematode species are differentiated based on morphometry and the presence or absence...
3.
Cunha B, Fonseca G, Amaral A
PeerJ
. 2023 Feb;
11:e14712.
PMID: 36846449
Cyatholaimidae is a common and diverse family of mainly marine nematodes, potentially, with a large number of species to be discovered. The taxonomy of the group is marked by a...
4.
Bahlis N, Siegel D, Schiller G, Samaras C, Sebag M, Berdeja J, et al.
Leuk Lymphoma
. 2022 Feb;
63(6):1407-1417.
PMID: 35133221
Patients with relapsed/refractory multiple myeloma (RRMM) need proven subsequent therapies after early-line lenalidomide treatment failure. The phase 2 MM-014 trial (NCT01946477) investigated pomalidomide, dexamethasone, and daratumumab after 1 to 2...
5.
Andersen I, Ishii N, Brooks T, Cummis C, Fonseca G, Hillers A, et al.
Natl Sci Rev
. 2021 Oct;
8(7):nwaa186.
PMID: 34691682
No abstract available.
6.
Davids M, OConnor O, Jurczak W, Samaniego F, Fenske T, Zinzani P, et al.
Blood Adv
. 2021 Sep;
5(23):5332-5343.
PMID: 34547767
Phosphoinositide 3-kinase-δ (PI3Kδ) inhibitors are active in lymphoid malignancies, although associated toxicities can limit their use. Umbralisib is a dual inhibitor of PI3Kδ and casein kinase-1ε (CK1ε). This study analyzed...
7.
Bouca-Machado R, Branco D, Fonseca G, Fernandes R, Abreu D, Guerreiro T, et al.
Front Neurol
. 2021 Apr;
12:637620.
PMID: 33833729
Functional mobility (FM) is a concept that incorporates the capacity of a person to move independently and safely to accomplish tasks. It has been proposed as a Parkinson's disease (PD)...
8.
Fonseca M, Ferreira F, Choueri R, Fonseca G
Sci Total Environ
. 2021 Mar;
770:145245.
PMID: 33736403
The traditional sediment quality triad generally uses three lines of evidence (LOE) in the assessment, integrating environmental chemistry, ecology and ecotoxicology. However the assessment is performed without considering the multivariate...
9.
Fowler N, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves J, et al.
J Clin Oncol
. 2021 Mar;
39(15):1609-1618.
PMID: 33683917
Purpose: Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been hampered by poor long-term tolerability and toxicity, which interfere with...
10.
Vieira D, Gallucci F, Corte G, Checon H, Amaral A, Fonseca G
Mar Environ Res
. 2020 Dec;
163:105223.
PMID: 33302155
We tested the hypothesis that the ubiquity of marine meiofaunal nematodes and their indiscriminate passive dispersal create assemblages that are less limited by its environment; whereas the relatively smaller population...